B. Iglesias et al. / Tetrahedron 57 *2001) 3125±3130
3129
3.2.5. rac-1-Pyridin-3-yl-pentan-3-ol ,8). According to the
general procedure described above 4procedure A, Table 2,
708C, 2 h), starting from rac-1-penten-3-ol 5 40.10 g,
1.16 mmol), 3-bromopyridine 2b 40.22 g, 1.39 mmol),
Pd4PPh3)4 40.13 g, 0.12 mmol) and K2CO3 41.6 mL, 3 M
in H2O, 4.65 mmol), it was obtained 0.13 g 469%) of rac-
3.2.8. rac-1-Pyridin-4-yl-pentan-3-ol ,10). According to
the general procedure described above 4procedure A,
Table 2, 708C, 2 h), starting from rac-1-penten-3-ol 5
40.07 g, 0.87 mmol), 4-bromopyridine hydrochloride 2c´HCl
40.20 g, 1.05 mmol), Pd4PPh3)4 40.10 g, 0.09 mmol) and
K2CO3 41.45 mL, 3 M in H2O, 4.36 mmol), it was obtained
0.09 g 463%) of rac-1-pyridin-4-yl-pentan-3-ol 10, after
1-pyridin-3-yl-pentan-3-ol 8, after puri®cation bychroma-
tography4SiO , AcOEt). H NMR 4400 MHz, CDCl3) d
1
1
puri®cation bychromatography4SiO 2, AcOEt). H NMR
4400 MHz, CDCl3) d 0.96 4t, J7.4 Hz, 3H, 3H5), 1.4±1.8
2
0.88 4t, J7.4 Hz, 3H, 3H5), 1.40 4m, 2H, 2H4), 1.70 4m,
3H, 2H21OH), 2.60 4m, 1H, H1), 2.70 4m, 1H, H1), 3.50 4m,
0
4m, 5H, 2H412H21OH), 2.70 4m, 1H, H1), 2.80 4m, 1H,
0 0
H1), 3.50 4m, 1H, H3), 7.15 4m, 2H, H3 1H5 ), 8.49 4m, 2H,
1H, H3), 7.15 4dd, J7.7, 4.8 Hz, 1H, H5 ), 7.46 4d,
J7.7 Hz, 1H, H4 ), 8.40 4m, 2H, H2 1H6 ); 13C NMR
H2 1H6 ); 13C NMR 4100 MHz, CDCl3) d 9.8 4q, C5), 30.3
0
0
0
0
0
0
4t), 31.3 4t), 37.2 4t, C1), 71.8 4d, C3), 124.0 4d, C3 1C5 ),
0
4100 MHz, CDCl3) d 9.8 4q, C5), 29.1 4t), 30.3 4t), 38.1 4t,
0
0
C1), 71.8 4d, C3), 123.3 4d, C5 ), 136.0 4d, C4 ), 137.7 4s, C3 ),
0
0
0
0
149.1 4d, C2 1C6 ), 151.9 4s, C4 ); IR 4NaCl) n 3600±3100
4br, O±H), 2927 4s, C±H), 2875 4s, C±H), 1606 4s), 1560
4w), 1419 4s), 1341 4m), 1220 4m), 1121 4m), 1002 4m), 755
4s) cm21; MS m/z 4%) 166 4[M11]1, 11), 165 4M1, 4), 147
441), 136 435), 118 448), 107 430), 106 495), 105 430), 93
4100), 92 459), 80 428), 65 425); HRMS calcd for C10H15NO
165.1154, found 165.1156.
0
0
146.9 4d, C6 ), 149.6 4d, C2 ); IR 4NaCl) n 3600±3100 4br,
O±H), 2960 4s, C±H), 2926 4s, C±H), 2874 4s, C±H), 1579
4w), 1425 4m), 1342 4m), 1121 4m), 1030 4m), 713 4m)
cm21; MS m/z 4%) 166 4[M11]1, 5), 165 4M1, 1), 164
4[M21]1, 3), 149 49), 148 412), 147 497), 136 437), 118
454), 107 415), 106 462), 105 467), 93 437), 92 4100), 85
420), 83 432), 79 415), 62 425); HRMS calcd for
C10H16NO 4[M1H]1) 166.1232, found 166.1231.
3.2.9. 5-Iodo-30,50-O-,tetraisopropyldisiloxane-1,3-diyl)-
20-deoxyuridine ,11). To a solution of 5-iodo-20-deoxy-
uridine 40.05 g, 0.14 mmol) and imidazole 40.02 g,
0.31 mmol) in DMF 40.5 mL) was slowlyadded 1,3-dichloro-
1,1,3,3-tetraisopropyldisiloxane 40.05 mL, 0.15 mmol). After
12 h stirring, excess silylating agent was decomposed by
the addition of MeOH 41 mL), followed byAcOEt
41 mL). The solution was poured into a saturated aqueous
NaCl solution and it was then extracted with AcOEt 43£).
The combined organic layers were washed with brine, dried
4MgSO4) and evaporated. Puri®cation bycolumn chroma-
tography4SiO 2, 75:25 hexane/AcOEt) afforded 0.08 g
497%) of protected nucleoside 11 as a white solid 4mp
1828C; Et2O/hexane). 1H NMR 4400 MHz, CDCl3) d
3.2.6. 5-Pyridin-4-yl-pentan-1-ol ,9b). According to the
general procedure described above 4procedure A, Table 2,
708C, 4 h), the reaction of 4-penten-1-ol 1b 40.10 g,
1.16 mmol), 4-bromopyridine hydrochloride 2c´HCl 40.27 g,
1.40 mmol), Pd4PPh3)4 40.13 g, 0.12 mmol) and K2CO3
43.2 mL, 3 M in H2O, 9.30 mmol), afforded, after puri®cation
bychromatography4SiO , AcOEt), 0.18 g 494%) of 5-pyridin-
2
1
4-yl-pentan-1-ol 9b. H NMR 4400 MHz, CDCl3) d 1.4±1.7
4m, 7H, 2H212H312H41OH), 2.63 4t, J7.7 Hz, 2H, 2H5),
3.65 4t, J6.5 Hz, 2H, 2H1), 7.11 4d, J5.8 Hz, 2H,
H3 1H5 ), 8.48 4d, J5.8 Hz, 2H, H2 1H6 ); 13C NMR
4100 MHz, CDCl3) d 25.2 4t), 29.8 4t), 32.3 4t), 34.9 4t,
0
0
0
0
0
1.0±1.1 4m, 28H, 4£i-Pr), 2.2±2.3 4m, 1H, H2 ), 2.4±2.5
0
C5), 61.8 4t, C1), 123.8 4d, C3 1C5 ), 149.0 4d, C2 1C6 ),
0
151.7 4s, C4 ); IR 4NaCl) n 3600±3100 4br, O±H), 2928
4s, C±H), 2859 4s, C±H), 1608 4m), 1446 4m), 1064 4m),
1006 4s), 752 4m) cm21; MS m/z 4%) 166 4[M11]1, 4), 165
4M1, 20), 164 4[M ± 1]1, 11), 147 413), 119 413), 118 425),
106 4100), 105 470), 93 456), 92 417), 65 413); HRMS calcd
for C10H15NO 165.1154, found 165.1153.
0
0
0
0
0
4m, 1H, H2 ), 3.7±3.8 4m, 1H, H3 ), 4.01 4dd, J13.2,
0
0
2.9 Hz, 1H, H5 ), 4.13 4dd, J13.2, 2.2 Hz, 1H, H5 ),
0
0
4.4±4.5 4m, 1H, H4 ), 6.00 4dd, J7.2, 1.7 Hz, 1H, H1 ),
8.01 4s, 1H, H6), 9.18 4br s, 1H, N±H); 13C NMR
4100 MHz, CDCl3) d 12.4 4d), 12.8 4d), 13.0 4d), 13.5 4d),
16.8 4q), 16.9 4q), 17.0 4q), 17.1 4q), 17.2 4q), 17.4 4q), 17.6
0
0
4q), 17.7 4q), 39.9 4t, C2 ), 59.9 4t, C5 ), 67.1 4d), 68.0 4s, C5),
84.7 4d), 85.3 4d), 144.0 4d, C6), 149.8 4s), 160.1 4s); IR
4NaCl) n 3200±3100 4br), 3100±3000 4br), 2945 4m,
C±H), 2867 4m, C±H), 2360 4m), 1698 4s, CO), 1605 4w),
1461 4m), 1270 4m), 1119 4m), 1038 4s), 887 4m), 773 4m),
698 4m), 612 4w) cm21; MS m/z 4%) 597 4[M11]1, 7), 553
48), 481 411), 455 444), 359 415), 329 410), 315 422), 287
468), 261 4100), 239 426), 217 413), 189 417), 175 432), 135
457), 119 471); HRMS calcd for C21H37N2IO6Si2 4[M1H]1)
597.1313, found 597.1306.
3.2.7. 6-Pyridin-4-yl-hexan-1-ol ,9c). Following the general
procedure described above 4procedure A, Table 2, 708C, 2 h),
starting from 5-hexen-1-ol 1c 40.05 g, 0.5 mmol), 4-bromo-
pyridine hydrochloride 2c´HCl 40.12 g, 0.6 mmol), Pd4PPh3)4
40.06 g, 0.05 mmol) and K2CO3 40.84 mL, 3 M in H2O,
2.5 mmol), it was obtained 0.07 g 478%) of 6-pyridin-4-yl-
hexan-1-ol 9c, after puri®cation bychromatography4SiO
,
2
1
AcOEt). H NMR 4400 MHz, CDCl3) d 1.3±1.7 4m, 8H,
2H212H312H412H5), 2.61 4t, J7.7 Hz, 2H, 2H6), 3.65 4t,
0
0
3.2.10. 6-Pyrimidin-5-yl-hexan-1-ol ,15). According to the
general procedure described above 4procedure B, 1008C,
19.5 h), the reaction of 5-hexen-1-ol 1c 40.08 g, 0.75 mmol),
5-bromopyrimidine 14 40.08 g, 0.50 mmol), Pd4OAc)2
40.005 g, 0.02 mmol), K3PO4 40.21 g, 1.00 mmol) and 2-
4di-tert-butylphosphino)biphenyl 40.01 g, 0.04 mmol) in
toluene 41.5 mL), afforded, after puri®cation bychroma-
tography4SiO 2, 97:3 CH2Cl2/MeOH), 0.05 g 455%) of
6-pyrimidin-5-yl-hexan-1-ol 15. 1H NMR 4400 MHz,
CDCl3) d 1.3±1.7 4m, 8H, 2H212H312H412H5), 2.62 4t,
J6.5 Hz, 2H, 2H1), 7.10 4d, J5.5 Hz, 2H, H3 1H5 ), 8.48
4d, J5.5 Hz, 2H, H2 1H6 ); 13C NMR 4100 MHz, CDCl3) d
0
0
25.5 4t), 28.8 4t), 30.1 4t), 32.5 4t, C2), 35.0 4t, C6), 62.4 4t, C1),
0
0
0
0
0
123.9 4d, C3 1C5 ), 149.3 4d, C2 1C6 ), 151.7 4s, C4 ); IR
4NaCl) n 3600±3100 4br, O±H), 2931 4s, C±H), 2858 4s,
C±H), 1606 4s), 1558 4w), 1418 4m), 1057 4m), 1003 4m),
724 4w) cm21; MS m/z 4%) 179 4M1, 9), 178 4[M 2 1]1, 9),
120 412), 118 410), 107 411), 106 4100), 105 421), 93 484), 92
415), 85 439), 83 461), 65 412); HRMS calcd for C11H17NO
179.1310, found 179.1305.